CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pharmasset, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pharmasset, Inc.
303-A, College Road East
Phone: (609) 613-4100p:609 613-4100 Princeton, NJ  08540  United States Fax: (609) 613-4150f:609 613-4150

This company was Merged or Acquired on 1/17/2012.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Pharmasset, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs to treat viral infections. The Company focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. The Company has three clinical-stage product candidates. It also has a series of preclinical candidates in preparation for clinical development. The three clinical product candidates include RG7128, PSI-7977 and PSI-938. In January 2012, Gilead Sciences, Inc. acquired Pharmasset, Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20119/30/2011YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Director John F.Milligan 50 1/13/2012 1/12/2012
Chief Financial Officer, Director Robin L.Washington 49 1/13/2012 1/12/2012
Secretary, Director Brett A.Pletcher 1/13/2012 1/12/2012
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Pharmasset Inc
Pharmasset Inc.
VRUS

General Information
Number of Employees: 82 (As of 9/30/2011)
Outstanding Shares: 75,657,230 (As of 10/31/2011)
Shareholders: 21
Stock Exchange: NASD
Federal Tax Id: 980406340
Fax Number: (609) 613-4150


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023